IMPrimary vaccination Consists of 2 doses of 0.5 mL each; an initial dose followed by a 2nd dose 2-6 mth later. For patients who are immunodeficient, immunosuppressed or likely to become immunosuppressed due to known disease or therapy, & whom would benefit from shorter vaccination schedule, 2nd dose can be given 1-2 mth after initial dose.
Not indicated for prevention of primary varicella infection. Postpone vaccination in subjects suffering from acute febrile illness. Protective immune response may not be elicited in all vaccinees. Do not administer intravascularly, intradermally or SC. Individuals w/ thrombocytopenia or any coagulation disorder. Syncope. Pregnancy & lactation. Increased risk of Guillain-Barré syndrome in a post-marketing observational study in individuals ≥65 yr during the 42 days following Shingrix vaccination. Insufficient information to establish causal relationship w/ Shingrix.